Samsung Biologics Co.,Ltd. (207940.KS)
KRW 1035000.0
(-1.05%)
KRW 1035000.0
(-1.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1909.33 Billion KRW | -24.05% |
| 2022 | 2514.03 Billion KRW | 94.47% |
| 2021 | 1292.74 Billion KRW | 64.7% |
| 2020 | 784.9 Billion KRW | 20.07% |
| 2019 | 653.7 Billion KRW | -25.09% |
| 2018 | 872.69 Billion KRW | 59.86% |
| 2017 | 545.91 Billion KRW | -35.25% |
| 2016 | 843.05 Billion KRW | 21.85% |
| 2015 | 691.9 Billion KRW | 45.44% |
| 2014 | 475.72 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1681.52 Billion KRW | -1.65% |
| 2024 Q1 | 1709.78 Billion KRW | -10.45% |
| 2023 Q2 | 2368.78 Billion KRW | -3.25% |
| 2023 Q3 | 2195.64 Billion KRW | -7.31% |
| 2023 Q4 | 1909.33 Billion KRW | -13.04% |
| 2023 FY | 1909.33 Billion KRW | -24.05% |
| 2023 Q1 | 2448.41 Billion KRW | -2.61% |
| 2022 FY | 2514.03 Billion KRW | 94.47% |
| 2022 Q4 | 2514.03 Billion KRW | 1.36% |
| 2022 Q3 | 2480.19 Billion KRW | 11.01% |
| 2022 Q1 | 1293.16 Billion KRW | 0.03% |
| 2022 Q2 | 2234.24 Billion KRW | 72.77% |
| 2021 Q2 | 597.41 Billion KRW | -20.2% |
| 2021 Q4 | 1292.74 Billion KRW | 8.36% |
| 2021 Q1 | 748.68 Billion KRW | -4.62% |
| 2021 FY | 1292.74 Billion KRW | 64.7% |
| 2021 Q3 | 1193.01 Billion KRW | 99.7% |
| 2020 Q1 | 608.5 Billion KRW | -6.92% |
| 2020 Q2 | 591.08 Billion KRW | -2.86% |
| 2020 Q3 | 610 Billion KRW | 3.2% |
| 2020 FY | 784.9 Billion KRW | 20.07% |
| 2020 Q4 | 784.9 Billion KRW | 28.67% |
| 2019 Q4 | 653.7 Billion KRW | -8.61% |
| 2019 FY | 653.7 Billion KRW | -25.09% |
| 2019 Q3 | 715.26 Billion KRW | -12.91% |
| 2019 Q2 | 821.3 Billion KRW | -5.12% |
| 2019 Q1 | 865.61 Billion KRW | -0.81% |
| 2018 FY | 872.69 Billion KRW | 59.86% |
| 2018 Q1 | 666.48 Billion KRW | 22.09% |
| 2018 Q2 | 891.59 Billion KRW | 33.78% |
| 2018 Q3 | 884.81 Billion KRW | -0.76% |
| 2018 Q4 | 872.69 Billion KRW | -1.37% |
| 2017 Q2 | 467.57 Billion KRW | -15.56% |
| 2017 Q1 | 553.71 Billion KRW | -34.32% |
| 2017 FY | 545.91 Billion KRW | -35.25% |
| 2017 Q3 | 497.75 Billion KRW | 6.45% |
| 2017 Q4 | 545.91 Billion KRW | 9.67% |
| 2016 FY | 843.05 Billion KRW | 21.85% |
| 2016 Q4 | 843.05 Billion KRW | 0.0% |
| 2015 FY | 691.9 Billion KRW | 45.44% |
| 2014 FY | 475.72 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | -62712.962% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | -49.147% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | -163.712% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -62961.388% |
| Green Cross Corporation | 724.02 Billion KRW | -163.712% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | -11026.914% |
| Celltrion, Inc. | 1890.42 Billion KRW | -1.0% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | -9180.53% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | -972.357% |
| Prestige BioPharma Limited | 89.66 Billion KRW | -2029.356% |